Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) CEO John C.M. Farquhar sold 22,562 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $27.75, for a total value of $626,095.50. Following the completion of the sale, the chief executive officer directly owned 435,373 shares of the company’s stock, valued at approximately $12,081,600.75. This represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
John C.M. Farquhar also recently made the following trade(s):
- On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00.
- On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.50, for a total value of $643,017.00.
- On Monday, May 11th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $29.12, for a total value of $657,005.44.
Heartflow Trading Down 2.1%
HTFL stock opened at $26.16 on Tuesday. The stock’s 50 day simple moving average is $30.12 and its 200 day simple moving average is $28.62. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $41.22. The firm has a market cap of $2.26 billion and a P/E ratio of -8.41.
Institutional Investors Weigh In On Heartflow
A number of hedge funds have recently made changes to their positions in HTFL. Handelsbanken Fonder AB acquired a new position in shares of Heartflow during the second quarter worth approximately $910,000. Essential Partners LLC acquired a new stake in Heartflow in the 1st quarter valued at approximately $57,000. Bank of America Corp DE increased its position in Heartflow by 28.8% in the 1st quarter. Bank of America Corp DE now owns 111,702 shares of the company’s stock valued at $2,718,000 after acquiring an additional 24,964 shares during the period. Janus Henderson Group PLC raised its stake in Heartflow by 152.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock valued at $53,063,000 after acquiring an additional 1,315,416 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in Heartflow by 41.9% during the 1st quarter. California State Teachers Retirement System now owns 29,371 shares of the company’s stock worth $715,000 after acquiring an additional 8,678 shares during the period.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on HTFL shares. Wells Fargo & Company increased their price objective on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Weiss Ratings downgraded Heartflow from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 8th. Piper Sandler reaffirmed an “overweight” rating on shares of Heartflow in a report on Thursday, June 11th. Canaccord Genuity Group dropped their price target on Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Finally, William Blair assumed coverage on Heartflow in a research report on Monday, May 4th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Heartflow presently has an average rating of “Moderate Buy” and a consensus target price of $37.00.
View Our Latest Analysis on HTFL
About Heartflow
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Further Reading
- Five stocks we like better than Heartflow
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
